Investment Thesis
STAAR Surgical maintains a fortress balance sheet with 73.6% gross margins and zero debt, but faces significant operational headwinds with 23.7% revenue decline and persistent negative operating cash flow of -$21.7M despite positive net income. The gap between accounting profits and negative free cash flow, combined with a 295% EPS collapse, suggests structural challenges requiring operational stabilization before bullish reassessment.
Strengths
- Industry-leading gross margins of 73.6% indicating strong product pricing power and manufacturing efficiency
- Fortress balance sheet with $131.9M cash, zero long-term debt, and 5.12x current ratio providing substantial financial flexibility
- Ophthalmic medical device sector with essential product demand and recurring revenue characteristics
Risks
- Revenue declined 23.7% YoY with diluted EPS plummeting 295%, indicating severe market or competitive headwinds
- Operating cash flow of -$21.7M coupled with negative free cash flow despite $5.2M net income signals quality-of-earnings concerns and potential working capital deterioration
- Operating margin compression to 8.5% from substantially higher historical levels suggests fixed cost burden or pricing pressure not yet reflected in gross margins
Key Metrics to Watch
- Operating cash flow return to positive territory and free cash flow stabilization
- Revenue growth inflection and customer retention metrics to confirm downturn reversing
- Gross margin sustainability above 70% to ensure no deterioration in competitive position
Financial Metrics
Revenue
93.5M
Net Income
5.2M
EPS (Diluted)
$0.10
Free Cash Flow
-22.1M
Total Assets
451.1M
Cash
131.9M
Profitability Ratios
Gross Margin
73.6%
Operating Margin
8.5%
Net Margin
5.6%
ROE
1.5%
ROA
1.2%
FCF Margin
-23.7%
Balance Sheet & Liquidity
Current Ratio
5.12x
Quick Ratio
4.55x
Debt/Equity
0.00x
Debt/Assets
21.9%
Interest Coverage
71.24x
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-14T07:11:22.404865 |
Data as of: 2026-04-03 |
Powered by Claude AI